-

Applied DNA to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced that Dr. James A. Hayward, president and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually from September 13 – 15, 2021.

A webcast of the virtual presentation will be available starting at 7:00 am (EST) on September 13, 2021, and can be accessed through the Investors Relations section of Applied DNA website at www.adnas.com or directly through the webcast link. An archived replay of the webcast will be available on the Company’s website after the conference.

About Applied DNA Sciences

Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction (“PCR”)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.

The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies.

The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.

Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle™, a pooled COVID-19 testing program that is grounded in the Company’s EUA-authorized Linea™ COVID-19 Assay Kit. safeCircle is designed to look for infection within defined populations or communities utilizing pooled testing methodologies that increase testing efficiencies. The Company has also developed and plans to seek EUA-authorization for its Linea™ SARS-CoV-2 Mutation Panel, an assay-based panel for the detection of certain SARS-CoV-2 genetic mutations.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under ticker symbol ‘APDN,’ and its publicly traded warrants are listed on OTC under ticker symbol ‘APPDW.’

Applied DNA is a member of the Russell Microcap® Index.

Contacts

For Applied DNA:
Investor: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web: www.adnas.com
Twitter: @APDN

Industry:

APPLIED DNA SCIENCES, INC.

NASDAQ:APDN
Details
Headquarters: Stony Brook, New York
Website: www.adnas.com
CEO: James Hayward
Employees: 69
Organization: PUB
Revenues: $18,168,677 (2022)
Net Income: $(8,270,059) (2022)
Release Summary
Applied DNA CEO to present at upcoming H.C. Wainwright 23rd Annual Global Investment Conference (virtual).
Release Versions
English
$Cashtags
$APDN
Hashtags
#COVID19Testing
#COVIDDiagnostics
#linearDNA

Contacts

For Applied DNA:
Investor: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web: www.adnas.com
Twitter: @APDN

Social Media Profiles
APDN - LinkedIn
APDN - twitter
More News From APPLIED DNA SCIENCES, INC.

Applied DNA to Report Second Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, May 11, 2023

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended March 31, 2023 after the market close on Thursday, May 11, 2023. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. ET. Date & Time: Thursday, May 11 @ 4:30 p.m....

Applied DNA's CertainT® Supply Chain Traceability Platform Featured in New York Times Article About the Need for Transparency and Compliance in Global Supply Chains Under Recently Passed U.S. Federal Regulation

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in PCR-based DNA technologies, announced that its CertainT® supply chain traceability platform is featured in an article on the home page of the New York Times website today. The article, titled "How A.I. and DNA Are Unlocking the Mysteries of Global Supply Chains," centers on the mounting need for the textile and other industries to employ tracing technologies to ensure compliance with the U...

Applied DNA Achieves Milestone for Large-Scale linearDNA™ Production, Delivers Largest Single Shipment by Volume to Date

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that it has established a new high bar for the production of DNA with the manufacture and shipment of a multi-gram quantity of linearDNA™ in under six weeks. The quantity was produced by the Company’s LinearDNA™ platform under a large recurring purchase order with a global manufacturer of in vitro diagnostics that was announced in the first quart...
Back to Newsroom